Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid

NCT06643884 is registered in ClinicalTrials.gov with Aura Biosciences as lead sponsor.

NCT NCT06643884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06643884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid
Lead sponsor
Aura Biosciences
Phase
Phase 2
Overall status
Recruiting
Start date
December 16, 2024
Completion date
October 31, 2027
Enrollment
24 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

eye cancer, primary cancer